ID   T241
AC   CVCL_M975
SY   ATC241
DR   Cosmic; 1239979
DR   Cosmic; 2054112
DR   Cosmic; 2186784
DR   Wikidata; Q54971460
RX   PubMed=17406368;
RX   PubMed=23833040;
RX   PubMed=25365311;
RX   PubMed=30737244;
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Asp252fs (c.756delT); Zygosity=Homozygous (PubMed=30737244).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Heterozygous; Note=In promoter (PubMed=23833040; PubMed=30737244).
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: In situ; Thyroid gland; UBERON=UBERON_0002046.
ST   Source(s): PubMed=25365311; PubMed=30737244
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D13S317: 12
ST   D16S539: 9
ST   D18S51: 19
ST   D21S11: 30
ST   D3S1358: 15
ST   D5S818: 13
ST   D7S820: 11
ST   D8S1179: 12
ST   FGA: 21
ST   TH01: 9.3
ST   TPOX: 8
ST   vWA: 15
DI   NCIt; C3878; Thyroid gland anaplastic carcinoma
DI   ORDO; Orphanet_142; Anaplastic thyroid carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   72Y
CA   Cancer cell line
DT   Created: 05-11-13; Last updated: 29-06-23; Version: 16
//
RX   PubMed=17406368; DOI=10.1038/sj.bjc.6603578;
RA   Rodrigues R.F., Roque L., Krug T., Leite V.;
RT   "Poorly differentiated and anaplastic thyroid carcinomas: chromosomal
RT   and oligo-array profile of five new cell lines.";
RL   Br. J. Cancer 96:1237-1245(2007).
//
RX   PubMed=23833040; DOI=10.1210/jc.2013-2383;
RA   Landa I., Ganly I., Chan T.A., Mitsutake N., Matsuse M.,
RA   Ibrahimpasic T., Ghossein R.A., Fagin J.A.;
RT   "Frequent somatic TERT promoter mutations in thyroid cancer: higher
RT   prevalence in advanced forms of the disease.";
RL   J. Clin. Endocrinol. Metab. 98:E1562-E1566(2013).
//
RX   PubMed=25365311; DOI=10.1210/jc.2014-2359;
RA   Garg M., Okamoto R., Nagata Y., Kanojia D., Venkatesan S., Anand M.T.,
RA   Braunstein G.D., Said J.W., Doan N.B., Ho Q., Akagi T., Gery S.,
RA   Liu L.-Z., Tan K.T., Chang W.J., Yang H., Ogawa S., Koeffler H.P.;
RT   "Establishment and characterization of novel human primary and
RT   metastatic anaplastic thyroid cancer cell lines and their genomic
RT   evolution over a year as a primagraft.";
RL   J. Clin. Endocrinol. Metab. 100:725-735(2015).
//
RX   PubMed=30737244; DOI=10.1158/1078-0432.CCR-18-2953;
RA   Landa I., Pozdeyev N., Korch C.T., Marlow L.A., Smallridge R.C.,
RA   Copland J.A. III, Henderson Y.C., Lai S.Y., Clayman G.L., Onoda N.,
RA   Tan A.-C., Garcia-Rendueles M.E.R., Knauf J.A., Haugen B.R.,
RA   Fagin J.A., Schweppe R.E.;
RT   "Comprehensive genetic characterization of human thyroid cancer cell
RT   lines: a validated panel for preclinical studies.";
RL   Clin. Cancer Res. 25:3141-3151(2019).
//